Nanoparticle Preconditioning for Enhanced Thermal Therapies in Cancer

• Ferrari M : Cancer nanotechnology: opportunities and challenges.Nat. Rev. Cancer5(3), 161–171 (2005).
   PubMed Web of Science ®Google Scholar
• Nie S , XingY, KimGJ, SimonsJW: Nanotechnology applications in cancer.Annu. Rev. Biomed. Eng.9, 257–288 (2007).
   PubMed Web of Science ®Google Scholar
• Xie J , LeeS, ChenX: Nanoparticle-based theranostic agents.Adv. Drug Deliv. Rev.62(11), 1064–1079 (2010).
   PubMed Web of Science ®Google Scholar
• Juzenas P , ChenW, SunYPet al.: Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer.Adv. Drug Deliv. Rev.60(15), 1600–1614 (2008).
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures 2009. American Cancer Society, Atlanta, GA, USA (2009).
   Google Scholar
• VanSonnenberg E , McMullenW, SolbiatiL: Tumor Ablation: Principles and Practice. Springer, NY, USA (2005).
   Google Scholar
• Mulier S , NiY, JamartJ, RuersT, MarchalG, MichelL: Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.Ann. Surg.242(2), 158–171 (2005).
   PubMed Web of Science ®Google Scholar
• Jones JS , RewcastleJC, DonnellyBJ, LugnaniFM, PistersLL, KatzAE: Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.J. Urol.180(2), 554–558 (2008).
   PubMed Web of Science ®Google Scholar
• Dewey WC : Arrhenius relationships from the molecule and cell to the clinic.Int. J. Hyperthermia10(4), 457–483 (1994).
   PubMed Web of Science ®Google Scholar
• Gage AA , BaustJG: Cryosurgery for tumors.J. Am. Coll. Surg.205(2), 342–356 (2007).
   PubMed Web of Science ®Google Scholar
• Day ES , MortonJG, WestJL: Nanoparticles for thermal cancer therapy.J. Biomech. Eng.131(7), 074001 (2009).
   PubMed Web of Science ®Google Scholar
• Gilchrist RK , MedalR, ShoreyWD, HanselmanRC, ParrottJC, TaylorCB: Selective inductive heating of lymph nodes.Ann. Surg.146(4), 596–606 (1957).
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K , RotheR, ScholzRet al.: Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme.J. Neurooncol.81(1), 53–60 (2007).
   PubMed Web of Science ®Google Scholar
• Johannsen M , GneveckowU, TaymoorianKet al.: Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial.Int. J. Hyperthermia23(3), 315–323 (2007).
   PubMed Web of Science ®Google Scholar
• Zharov VP , GalitovskayaEN, JohnsonC, KellyT: Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: potential for cancer therapy.Lasers Surg. Med.37(3), 219–226 (2005).
   PubMed Web of Science ®Google Scholar
• Skrabalak SE , ChenJ, AuL, LuX, LiX, XiaY: Gold nanocages for biomedical applications.Adv. Mater. Deerfield19(20), 3177–3184 (2007).
   PubMed Web of Science ®Google Scholar
• Huang X , El-SayedIH, QianW, El-SayedMA: Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods.J. Am. Chem. Soc.128(6), 2115–2120 (2006).
   PubMed Web of Science ®Google Scholar
• Huang N , WangH, ZhaoJ, LuiH, KorbelikM, ZengH: Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma.Lasers Surg. Med.42(9), 638–648 (2010).
   PubMed Web of Science ®Google Scholar
• von Maltzahn G , ParkJH, AgrawalAet al.: Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas.Cancer Res.69(9), 3892–3900 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou M , ZhangR, HuangMet al.: A chelator-free multifunctional [(64)Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy.J. Am. Chem. Soc.132(43), 15351–15358 (2010).
   PubMed Web of Science ®Google Scholar
• Hirsch LR , StaffordRJ, BanksonJAet al.: Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance.Proc. Natl Acad. Sci. USA100(23), 13549–13554 (2003).
   PubMed Web of Science ®Google Scholar
• Curley SA , CherukuriP, BriggsKet al.: Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.J. Exp. Ther. Oncol.7(4), 313–326 (2008).
   PubMedGoogle Scholar
• Byrne JD , BncourtT, Brannon-PeppasL: Active targeting schemes for nanoparticle systems in cancer therapeutics.Adv. Drug Deliv. Rev.60(15), 1615–1626 (2008).
   PubMed Web of Science ®Google Scholar
• Issels RD : Hyperthermia adds to chemotherapy.Eur. J. Cancer44(17), 2546–2554 (2008).
   PubMed Web of Science ®Google Scholar
• Griffin RJ , OgawaA, WilliamsBW, SongCW: Hyperthermic enhancement of tumor radiosensitization strategies.Immunol. Invest.34(3), 343–359 (2005).
   PubMed Web of Science ®Google Scholar
• Dudar TE , JainRK: Differential response of normal and tumor microcirculation to hyperthermia.Cancer Res.44(2), 605–612 (1984).
   PubMed Web of Science ®Google Scholar
• Koning G , EggermontA, LindnerL, ten Hagen T: Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm. Res.27(8), 1750–1754 (2010).
   PubMed Web of Science ®Google Scholar
• Lin JC , YuanPMK, JungDT: Enhancement of anticancer drug delivery to the brain by microwave induced hyperthermia.Bioelectrochem. Bioenergetics47(2), 259–264 (1998).
   Web of Science ®Google Scholar
• Franckena M , De Wit R, Ansink AC et al.: Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int. J. Hyperthermia23(5), 443–450 (2007).
   PubMed Web of Science ®Google Scholar
• Sneed PK , StaufferPR, McDermottMWet al.: Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme.Int. J. Radiat. Oncol. Biol. Phys.40(2), 287–295 (1998).
   PubMed Web of Science ®Google Scholar
• van der Zee J , GonzalezGD, van Rhoon GC, van Dijk JD, van Putten WL, Hert AA: Comparison of radiotherapy alone with radiotherapy plus hyeprthermia in locally advanced pelvic tumors: a prospective, randomized, multicentre trial. Dutch Deep Hyperthemic Group. Lancet355(9210), 1119–1125 (2000).
   PubMed Web of Science ®Google Scholar
• Colombo R , Da Pozzo LF, Salonia A et al.: Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol.21(23), 4270–4276 (2003).
   PubMed Web of Science ®Google Scholar
• Ponce AM , VujaskovicZ, YuanF, NeedhamD, DewhirstMW: Hyperthermia mediated liposomal drug delivery.Int. J. Hyperthermia22(3), 205–213 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg SN , KamelIR, KruskalJBet al.: Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy.AJR Am. J. Roentgenol.179(1), 93–101 (2002).
   PubMed Web of Science ®Google Scholar
• Ahmed M , LukyanovAN, TorchilinV, TournierH, SchneiderAN, GoldbergSN: Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.J. Vasc. Interv. Radiol.16(10), 1365–1371 (2005).
   PubMed Web of Science ®Google Scholar
• Schwerdt A , ZintchenkoA, ConciaMet al.: Hyperthermia-induced targeting of thermosensitive gene carriers to tumors.Hum. Gene Ther.19(11), 1283–1292 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang W , RongJ, WangQ, HeX: The encapsulation and intracellular delivery of trehalose using a thermally responsive nanocapsule.Nanotechnology27, 275101 (2009).
   Google Scholar
• Hanna E , QuickJ, LibuttiSK: The tumour microenvironment: a novel target for cancer therapy.Oral Dis.15(1), 8–17 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang J , GoelR, IftekharMAet al.: Tumor necrosis factor-{α}-induced accentuation in cryoinjury: mechanisms in vitro and in vivo.Mol. Cancer Ther.7(8), 2547–2555 (2008).
   PubMed Web of Science ®Google Scholar
• Visaria R , BischofJC, LorenMet al.: Nanotherapeutics for enhancing thermal therapy of cancer.Int. J. Hyperthermia23(6), 501–511 (2007).
   PubMed Web of Science ®Google Scholar
• Visaria RK , GriffinRJ, WilliamsBWet al.: Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-{α} delivery.Mol. Cancer Ther.5(4), 1014–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Libutti SK , PaciottiGF, MyerLet al.: Results of a completed phase I clinical trial of CYT-6091: a PEGylated colloidal gold-TNF nanomedicine.J. Clin. Oncol.27, 15S; (suppl., abstract 3586) (2009).
   Web of Science ®Google Scholar
• Libutti SK , PaciottiGF, ByrnesAAet al.: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.Clin. Cancer Res.16(24), 6139–6149 (2010).
   PubMed Web of Science ®Google Scholar
• van Horssen R , Ten Hagen TL, Eggermont AM: TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist11(4), 397–408 (2006).
   PubMed Web of Science ®Google Scholar
• Lin JC , ParkHJ, SongCW: Combined treatment of IL-1 α and TNF-α potentiates the antitumour effect of hyperthermia.Int. J. Hyperthermia12(3), 335–344 (1996).
   PubMed Web of Science ®Google Scholar
• Sun Z , YanJ, RaoW, LiuJ: Particularities of tissue types in treatment planning of nano cryosurgery. In: Nano/Micro Engineered and Molecular Systems, 2008. NEMS 2008. 3rd IEEE International Conference. Sanya, China, 6–9 January 2008.
   Google Scholar
• Shalkevich N , EscherW, BurgiT, MichelB, Si-AhmedL, PoulikakosD: On the thermal conductivity of gold nanoparticle colloids.Langmuir26(2), 663–670 (2009).
   Web of Science ®Google Scholar
• Goel R , ShahN, VisariaR, PaciottiGF, BischofJC: Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system.Nanomedicine4(4), 401–410 (2009).
   PubMed Web of Science ®Google Scholar
• Perrault SD , WalkeyC, JenningsT, FischerHC, ChanWC: Mediating tumor targeting efficiency of nanoparticles through design.Nano Lett.9(5), 1909–1915 (2009).
   PubMed Web of Science ®Google Scholar
• De Jong WH , HagensWI, KrystekP, BurgerMC, SipsAJ, GeertsmaRE: Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.Biomaterials29(12), 1912–1919 (2008).
   PubMed Web of Science ®Google Scholar
• James W , HirschL, WestJ, O‘NealP, PayneJ: Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice.J. Radioanalyt. Nucl. Chem.271(2), 455–459 (2007).
   Web of Science ®Google Scholar
• Petros RA , DeSimoneJM: Strategies in the design of nanoparticles for therapeutic applications.Nat. Rev. Drug Discov.9(8), 615–627 (2010).
   PubMed Web of Science ®Google Scholar
• Paciotti GF , MyerL, WeinreichDet al.: Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery.Drug Deliv.11(3), 169–183 (2004).
   PubMed Web of Science ®Google Scholar
• Shah NB , DongJ, BischofJC: Cellular uptake and nanoscale localization of gold nanoparticles in cancer using label free Confocal Raman Microscopy.Mol. Pharm.8(1), 176–84 (2010).
   PubMedGoogle Scholar
• Pober JS , SessaWC: Evolving functions of endothelial cells in inflammation.Nat. Rev. Immunol.7(10), 803–815 (2007).
   PubMed Web of Science ®Google Scholar
• ten Hagen TL , SeynhaeveAL, EggermontAM: Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Immunol. Rev.222, 299–315 (2008).
   PubMed Web of Science ®Google Scholar
• Farma JM , PuhlmannM, SorianoPAet al.: Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor.Int. J. Cancer120(11), 2474–2480 (2007).
   PubMed Web of Science ®Google Scholar
• Griffin RJ , LeeSH, RoodKLet al.: Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.Neoplasia2(6), 555–560 (2000).
   PubMed Web of Science ®Google Scholar
• Griffin RJ , MonzenH, WilliamsBW, ParkH, LeeSH, SongCW: Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours.Int. J. Hyperthermia19(6), 575–589 (2003).
   PubMed Web of Science ®Google Scholar
• Griffin RJ , WilliamsBW, BischofJC, OlinM, JohnsonGL, LeeBW: Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy.Technol. Cancer Res. Treat.6(6), 651–654 (2007).
   PubMed Web of Science ®Google Scholar
• Hines-Peralta A , SukhatmeV, ReganM, SignorettiS, LiuZJ, GoldbergSN: Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.Radiology240(1), 82–89 (2006).
   PubMed Web of Science ®Google Scholar
• Hinnen P , EskensFA: Vascular disrupting agents in clinical development.Br. J. Cancer96(8), 1159–1165 (2007).
   PubMed Web of Science ®Google Scholar
• Siemann DW : The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents.Cancer Treat. Rev. (2010) (In press).
   PubMed Web of Science ®Google Scholar
• Shalaby MR , PalladinoMA Jr, Hirabayashi SE et al.: Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-α. J. Leukoc. Biol.41(3), 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Jiang J , GoelR, SchmechelS, VercellottiG, ForsterC, BischofJ: Pre-conditioning cryosurgery: cellular and molecular mechanisms and dynamics of TNF-α enhanced cryotherapy in an in vivo prostate cancer model system.Cryobiology61(3), 280–288 (2010).
   PubMed Web of Science ®Google Scholar
• Di Carlo E , ForniG, LolliniP, ColomboMP, ModestiA, MusianiP: The intriguing role of polymorphonuclear neutrophils in antitumor reactions.Blood97(2), 339–345 (2001).
   PubMed Web of Science ®Google Scholar
• Allavena P , SicaA, GarlandaC, MantovaniA: The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.Immunol. Rev.222, 155–161 (2008).
   PubMed Web of Science ®Google Scholar
• Boon T , CouliePG, Van den Eynde BJ, van der Bruggen P: Human T cell responses against melanoma. Annu. Rev. Immunol.24, 175–208 (2006).
   PubMed Web of Science ®Google Scholar
• Balza E , MortaraL, SassiFet al.: Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.Clin. Cancer Res.12(8), 2575–2582 (2006).
   PubMed Web of Science ®Google Scholar
• Yang JC , HughesM, KammulaUet al.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.J. Immunother.30(8), 825–830 (2007).
   PubMed Web of Science ®Google Scholar
• Lei C , LiuP, ChenBet al.: Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.J. Am. Chem. Soc.132(20), 6906–6907 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffmann NE , BischofJC: The cryobiology of cryosurgical injury.Urology60(2 Suppl. 1), 40–49 (2002).
   PubMedGoogle Scholar
• Nikfarjam M , MuralidharanV, ChristophiC: Mechanisms of focal heat destruction of liver tumors.J. Surg. Res.127(2), 208–223 (2005).
   PubMed Web of Science ®Google Scholar
• Gage AA , BaustJM, BaustJG: Experimental cryosurgery investigations in vivo.Cryobiology59(3), 229–243 (2009).
   PubMed Web of Science ®Google Scholar
• Lepock J : Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage.Int. J. Hyperthermia19(3), 252–266 (2003).
   PubMed Web of Science ®Google Scholar
• Coad JE , KosariK, HumarA, SielaffTD: Radiofrequency ablation causes ‘thermal fixation’ of hepatocellular carcinoma: a post-liver transplant histopathologic study.Clin. Transplant.17(4), 377–384 (2003).
   PubMed Web of Science ®Google Scholar
• Gazzaniga S , BravoA, GoldszmidSet al.: Inflammatory changes after cryosurgery-induced necrosis in human melanoma xenografted in nude mice.J. Invest. Dermatol.116(5), 664–671 (2001).
   PubMed Web of Science ®Google Scholar
• Esmon C : The interactions between inflammation and coagulation.Br. J. Haematol.131(4), 417–430 (2005).
   PubMed Web of Science ®Google Scholar
• Sabel MS : Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses.Cryobiology58(1), 1–11 (2009).
   PubMed Web of Science ®Google Scholar
• Skitzki JJ , RepaskyEA, EvansSS: Hyperthermia as an immunotherapy strategy for cancer.Curr. Opin. Investig. Drugs10(6), 550–558 (2009).
   PubMedGoogle Scholar
• Gallucci S , LolkemaM, MatzingerP: Natural adjuvants: endogenous activators of dendritic cells.Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Shenoi MM , AndersonJK, BischofJC: Nanoparticle enhanced thermal therapies. In: Engineering in Medicine and Biology Society, 2009. EMBC 2009. Annual International Conference of the IEEE. Minneapolis, MN, USA, 3–6 September 2009.
   Google Scholar
• Pedro RN , Thekke-AdiyatT, GoelRet al.: Use of tumor necrosis factor-α-coated gold nanoparticles to enhance radiofrequency ablation in a translational model of renal tumors.Urology76(2), 494–498
   PubMed Web of Science ®Google Scholar
• Goel R , SwanlundD, CoadJ, PaciottiGF, BischofJC: TNF-α-based accentuation in cryoinjury – dose, delivery, and response.Mol. Cancer Ther.6(7), 2039–2047 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang J , BischofJ: Effect of timing, dose and interstitial versus nanoparticle delivery of tumor necrosis factor a in combinatorial adjuvant cryosurgery treatment of ELT-3 uterine fibroid tumor.Cryo Lett.31(1), 50–62 (2010).
   PubMed Web of Science ®Google Scholar
• Seshadri M , TothK: Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic acid in an orthotopic model of human head and neck cancer.Transl. Oncol.2(3), 121–127 (2009).
   PubMed Web of Science ®Google Scholar
• Salmon BA , SalmonHW, SiemannDW: Monitoring the treatment efficacy of the vascular disrupting agent CA4P.Eur. J. Cancer43(10), 1622–1629 (2007).
   PubMed Web of Science ®Google Scholar
• Gross S , GammonST, MossBLet al.: Bioluminescence imaging of myeloperoxidase activity in vivo.Nat. Med.15(4), 455–461 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez E , NilgesM, WeisslederR, ChenJW: Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.J. Am. Chem. Soc.132(1), 168–177 (2010).
   PubMed Web of Science ®Google Scholar
• Rubinsky B : Cryosurgery.Annu. Rev. Biomed. Eng.2, 157–187 (2000).
   PubMed Web of Science ®Google Scholar
• Gage AA , BaustJ: Mechanisms of tissue injury in cryosurgery.Cryobiology37(3), 171–186 (1998).
   PubMed Web of Science ®Google Scholar
• Baust JG , GageAA, KlossnerDet al.: Issues critical to the successful application of cryosurgical ablation of the prostate.Technol. Cancer Res. Treat.6(2), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Rewcastle JC , SandisonGA, HahnLJ, SalikenJC, McKinnonJG, DonnellyBJ: A model for the time-dependent thermal distribution within an iceball surrounding a cryoprobe.Phys. Med. Biol.43(12), 3519–3534 (1998).
   PubMed Web of Science ®Google Scholar
• Chao BH , HeX, BischofJC: Pre-treatment inflammation induced by TNF-α augments cryosurgical injury on human prostate cancer.Cryobiology49(1), 10–27 (2004).
   PubMed Web of Science ®Google Scholar
• Powell AC , PaciottiGF, LibuttiSK: Colloidal gold: a novel nanoparticle for targeted cancer therapeutics.Methods Mol. Biol.624, 375–384 (2010).
   PubMedGoogle Scholar
• Thamm DH , KurzmanID, ClarkMAet al.: Preclinical investigation of PEGylated tumor necrosis factor a in dogs with spontaneous tumors: Phase I evaluation.Clin. Cancer Res.16(5), 1498–1508 (2010).
   PubMed Web of Science ®Google Scholar
• Siemann DW , ChaplinDJ, HorsmanMR: Vascular-targeting therapies for treatment of malignant disease.Cancer100(12), 2491–2499 (2004).
   PubMed Web of Science ®Google Scholar
• Horsman MR , MurataR: Combination of vascular targeting agents with thermal or radiation therapy.Int. J. Radiat. Oncol. Biol. Phys.54(5), 1518–1523 (2002).
   PubMed Web of Science ®Google Scholar
• Murata R , OvergaardJ, HorsmanMR: Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.Int. J. Hyperthermia17(6), 508–519 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar V , FaustoN, AbbasA: Robbins and Cotran Pathologic Basis of Disease, Seventh Edition. Saunders, PA, USA (2004).
   Google Scholar
• Adams R , SchachtrupC, DavalosD, TsigelnyI, AkassoglouK: Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis.Curr. Med. Chem.14(27), 2925–2936 (2007).
   PubMed Web of Science ®Google Scholar
• Pallavicini MG , HillRP: Effect of tumor blood flow manipulations on radiation response.Int. J. Radiat. Oncol. Biol. Phys.9(9), 1321–1325 (1983).
   PubMed Web of Science ®Google Scholar
• Kano MR , BaeY, IwataCet al.: Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling.Proc. Natl Acad. Sci. USA104(9), 3460–3465 (2007).
   PubMed Web of Science ®Google Scholar
• Garay RP , ViensP, BauerJet al.: Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.Eur. J. Pharmacol.563(1–3), 1–17 (2007).
   PubMed Web of Science ®Google Scholar
• Moschella F , ProiettiE, CaponeI, BelardelliF: Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.Ann. NY Acad. Sci.1194, 169–178 (2010).
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG , SuciuS, TestoriAet al.: Phase III trial comparing adjuvant treatment with PEGylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies – EORTC 18991.J. Clin. Oncol.28(14), 2460–2466 (2010).
   PubMed Web of Science ®Google Scholar
• Agarwala SS , GlaspyJ, O‘DaySJet al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.J. Clin. Oncol.20(1), 125–133 (2002).
   PubMed Web of Science ®Google Scholar
• Yang JC , TopalianSL, SchwartzentruberDJet al.: The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A Phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.Cancer76(4), 687–694 (1995).
   PubMed Web of Science ®Google Scholar
• Cocco C , PistoiaV, AiroldiI: New perspectives for melanoma immunotherapy: role of IL-12.Curr. Mol. Med.9(4), 459–469 (2009).
   PubMed Web of Science ®Google Scholar
• Flavell RA , SanjabiS, WrzesinskiSH, Licona-LimonP: The polarization of immune cells in the tumour environment by TGFβ.Nat. Rev. Immunol.10(8), 554–567 (2010).
   PubMed Web of Science ®Google Scholar
• Hennessy EJ , ParkerAE, O‘NeillLA: Targeting Toll-like receptors: emerging therapeutics?Nat. Rev. Drug Discov.9(4), 293–307 (2010).
   PubMed Web of Science ®Google Scholar
• Redondo P , del Olmo J, Lopez-Diaz de Cerio A et al.: Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J. Invest. Dermatol.127(7), 1673–1680 (2007).
   PubMed Web of Science ®Google Scholar
• den Brok MH , SutmullerRP, NierkensSet al.: Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.Cancer Res.66(14), 7285–7292 (2006).
   PubMed Web of Science ®Google Scholar
• Udagawa M , Kudo-SaitoC, HasegawaGet al.: Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and bacillus Calmette–Guerin cell wall skeleton stimulation.Clin. Cancer Res.12(24), 7465–7475 (2006).
   PubMed Web of Science ®Google Scholar
• Yamanaka R , HommaJ, YajimaNet al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial.Clin. Cancer Res.11(11), 4160–4167 (2005).
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR , EngleX, ScarlettUKet al.: Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.J. Clin. Invest.119(8), 2231–2244 (2009).
   PubMed Web of Science ®Google Scholar
• Dominguez AL , LustgartenJ: Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.Vaccine28(5), 1383–1390 (2010).
   PubMed Web of Science ®Google Scholar
• Goel R , PaciottiGF, BischofJC: Tumor necrosis factor-α induced enhancement of cryosurgery.Proceedings SPIE6842, 68420R (2008).
   Google Scholar

Websites

• Celsion Corporation www.celsion.com (Accessed 8December2010)
   Google Scholar
• Galil Medical www.galil-medical.com
   Google Scholar
• HealthTronics www.endocare.com
   Google Scholar
• Sanarus www.sanarus.com
   Google Scholar
• Brymill Cryogenics Systems www.brymill.com
   Google Scholar
• ERBE Medical www.erbe-med.com
   Google Scholar
• Covidien www.valleylab.com
   Google Scholar
• Boston Scientific Corporation www.bostonscientific.com
   Google Scholar
• Angiodynamics www.angiodynamics.com
   Google Scholar
• Berchtold Corporation www.berchtoldusa.com
   Google Scholar
• Medtronic, Inc. www.medtronic.com
   Google Scholar
• EDAP TMS www.edap-tms.com
   Google Scholar
• InSightec www.insightec.com
   Google Scholar
• Philips www.philips.com
   Google Scholar
• Urologix, Inc. www.urologix.com
   Google Scholar
• Boston Scientific Corporation www.prolieve.com
   Google Scholar
• Ethicon Endo-Surgery, Inc. www.ethiconendo.com
   Google Scholar
• American Medical Systems www.greenlighthps.com
   Google Scholar
• Nanospectra Biosciences, Inc. www.nanospectra.com
   Google Scholar
• MagForce Nanotechnologies AG www.magforce.de
   Google Scholar